Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Hou, Hsin-An  [Clear All Filters]
2024
Yao C-Y, Lin C-C, Wang Y-H, Kao C-J, Tsai XCheng-Hong, Hou H-A, Tien H-F, Hsu C-L, Chou W-C. Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes. Blood Adv. 2024.
2023
Gill H, Leung GMK, Ooi MGM, Z Y Teo W, Wong C-L, Choi CWon, Wong G-C, Lao Z, Rojnuckarin P, Castillo MRosario Ir, et al. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group. Clin Exp Med. 2023.
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang M-C, Cairoli R, Hou H-A, Kwong Y-L, Arnan M, Meers S, et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2023.
Wang Y-H, Yao C-Y, Lin C-C, Gurashi K, Amaral FMR, Bossenbroek H, Jerez A, Somervaille TCP, Binder M, Patnaik MM, et al. A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia. Br J Haematol. 2023.
Lee W-H, Tsai M-T, Tsai C-H, Tien F-M, Lo M-Y, Tseng M-H, Kuo Y-Y, Liu M-C, Yang Y-T, Chen J-C, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification. Blood Cancer J. 2023;13(1):120.
2021
Wang Y-H, Hou H-A, Lin C-C, Kuo Y-Y, Yao C-Y, Hsu C-L, Tseng M-H, Tsai C-H, Peng Y-L, Kao C-J, et al. A CIBERSORTx-based immune-cell scoring system could independently predict prognosis of myelodysplastic syndrome patients. Blood Adv. 2021.
2020
Wang Y-H, Lin C-C, Yao C-Y, Hsu C-L, Hou H-A, Tsai C-H, Chou W-C, Tien H-F. A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. Blood Adv. 2020;4(4):644-654.
Hung S-Y, Lin C-C, Hsu C-L, Yao C-Y, Wang Y-H, Tsai C-H, Hou H-A, Chou W-C, Tien H-F. The expression levels of long non-coding RNA KIAA0125 are associated with distinct clinical and biological features in myelodysplastic syndromes. Br J Haematol. 2020.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou H-A, Eksioglu EAdriana, Sullivan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020.
2019
McGraw KL, Cheng C-H, Y Chen A, Hou H-A, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, et al. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. Blood Adv. 2019;3(22):3579-3589.
2016
Hou H-A, Liu C-Y, Kuo Y-Y, Chou W-C, Tsai C-H, Lin C-C, Lin L-I, Tseng M-H, Chiang Y-C, Liu M-C, et al. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia. Oncotarget. 2016.
2015
Chen Y-K, Hou H-A, Tang J-L, Jhuang J-Y, Lai Y-J, Lee M-C, Kuo Y-Y, Chou W-C, Liu C-Y, Lin C-W, et al. Clinical and Prognostic Implications of Roundabout 4 (Robo4) in Adult Patients with Acute Myeloid Leukemia. PLoS One. 2015;10(3):e0119831.
Tang J-L, Kung H-C, Lei W-C, Yao M, Wu U-I, Hsu S-C, Lin C-T, Li C-C, Wu S-J, Hou H-A, et al. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. PLoS One. 2015;10(6):e0128410.
Cheng C-L, Li C-C, Hou H-A, Fang W-Q, Chang C-H, Lin C-T, Tang J-L, Chou W-C, Chen C-Y, Yao M, et al. Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer. 2015;15(1):344.
2014
Kuo Y-Y, Hou H-A, Chen Y-K, Li L-Y, Chen P-H, Tseng M-H, Huang C-F, Lee F-Y, Liu M-C, Liu C-W, et al. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression. Haematologica. 2014.